NCT05948943 2026-04-14
EPIK-L1
Novartis
Phase 2/3 Recruiting
Clinical Trials
4 trialsNCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05508906 2025-10-22
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals, Inc.
Phase 1 Recruiting
NCT05293470 2025-07-09
A Post Marketing Surveillance on Piqray in Korea
Novartis
Recruiting